Photo from wikipedia
The journey of a thousand miles in lung cancer therapy began with the discovery of actionable genomic alterations. The two most well described molecular alterations are the epidermal growth factor… Click to show full abstract
The journey of a thousand miles in lung cancer therapy began with the discovery of actionable genomic alterations. The two most well described molecular alterations are the epidermal growth factor receptor (EGFR) mutation and ALK fusion [1,2]. Initially, we thought that these oncogenic drivers are mutually exclusive, i.e. only a single driver per tumor. However, we now know that tumors may harbor more than one molecular driver, including concurrent EGFR and ALK alterations [3–9]. We present a case series of patients with NSCLC with concurrent EGFR and ALK alterations.
Journal Title: Acta Oncologica
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!